DOI: https://doi.org/10.1038/s41598-023-44264-7 Drug repurposing: a nexus of innovation, science, and potential. De Rosa, M.C., Purohit, R. & García-Sosa, A.T. Sci Rep 13, 17887 (2023)

The urgency of finding therapeutic solutions for emerging and existing health challenges has never been more pronounced. In the pursuit of this goal, the value of a strategy that makes use of existing resources is being recognized: drug repurposing or repositioning of compounds for new indications. Such approaches are employed against cancer, rheumatoid arthritis, multiple sclerosis, HIV/AIDS, and many other diseases. This Collection, aptly titled “Drug Repurposing”, includes research and perspectives from scientists at the forefront of this innovative field.

The process of drug discovery, safety testing, and clinical trials is an extremely long and costly one. Drug repurposing, or drug repositioning, is an approach which aims to circumvent some of the steps of that process by examining previously approved compounds for their efficacy in new indications. By taking a systematic and computational approach to assessing the suitability of known compounds, researchers are able to speed up successful drug discovery and bring treatment options to patients who need them.

 

COST
What is COST?

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. The COST ACTIONS help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

OneHealthdrugs CA21111
Title:

One Health drugs against parasitic vector borne diseases in Europe and beyond

Acronym:

OneHealthdrugs

Start date of the Action:

24/10/2022

End date of the Action:

23/10/2026

CSO approval date:

27/05/2022

Memorandum of Understanding (MoU)

Download file

Contact Points
Chair:

Maria Paola Costi

Vice-Chair:

Anabela Cordeiro da Silva

COST staff

Scientific Officer:
Lucia Forzi
Administrative Officer:
Nathalie Warenghien

Administrative Team

Maria Cristina Notarsanto
Maria Esposito and Laura Leonardi